key: cord-0305603-4e06m4or
authors: Wu, Yu; Mahtal, Nassim; Swistak, Léa; Sagadiev, Sara; Acharya, Mridu; Demeret, Caroline; van der Werf, Sylvie; Guivel-Benhassine, Florence; Schwartz, Olivier; Petracchini, Serena; Mettouchi, Amel; Paillares, Eléa; Caramelle, Lucie; Couvineau, Pierre; Thai, Robert; Barbe, Peggy; Keck, Mathilde; Brodin, Priscille; Machelart, Arnaud; Sencio, Valentin; Trottein, François; Sachse, Martin; Chicanne, Gaëtan; Payrastre, Bernard; Ville, Florian; Kreis, Victor; Popoff, Michel-Robert; Johannes, Ludger; Cintrat, Jean-Christophe; Barbier, Julien; Gillet, Daniel; Lemichez, Emmanuel
title: A screening pipeline identifies a broad-spectrum inhibitor of bacterial AB toxins with cross protection against influenza A virus H1N1 and SARS-CoV-2
date: 2021-08-16
journal: bioRxiv
DOI: 10.1101/2021.08.13.454991
sha: 5e868daf735d9308bfd8092f909501ffe669801c
doc_id: 305603
cord_uid: 4e06m4or

A challenge for the development of host-targeted anti-infectives against a large spectrum of AB-like toxin-producing bacteria encompasses the identification of chemical compounds corrupting toxin transport through both endolysosomal and retrograde pathways. Here, we performed a high-throughput screening of small chemical compounds blocking active Rac1 proteasomal degradation triggered by the Cytotoxic Necrotizing Factor-1 (CNF1) toxin, followed by orthogonal screens against two AB toxins hijacking defined endolysosomal (Diphtheria toxin) or retrograde (Shiga-like toxin 1) pathways to intoxicate cells. This led to the identification of the molecule N-(3,3-diphenylpropyl)-1-propyl-4-piperidinamine, referred to as C910. This compound induces the swelling of EEA1-positive early endosomes, in absence of PIKfyve kinase inhibition, and disturbs the trafficking of CNF1 and the B-subunit of Shiga toxin along the endolysosomal or retrograde pathways, respectively. Together, we show that C910 protects cells against 8 bacterial AB toxins including large clostridial glucosylating toxins from Clostridium difficile. Of interest, C910 also reduced viral infection in vitro including influenza A virus subtype H1N1 and SARS-CoV-2. Moreover, parenteral administration of C910 to the mice resulted in its accumulation in lung tissues and reduced lethal influenza infection.

Host-directed anti-infective chemical compounds that interfere with intracellular membrane 68 trafficking hold promise to alleviate pathophysiological manifestations triggered by 69 bacterial toxins, thus shifting the host-pathogen balance in favor of the host (1) . 70 Furthermore, conservation of physicochemical requirements for cell invasion by pathogens 71 and toxins allows to re-direct small molecules targeting endocytic pathways against a 72 wider number of infectious agents notably viruses (2) (3) (4) . Discovery of such molecules is a 73 current challenge to expand available therapeutics against highly prevalent infections, 74 multidrug-resistant pathogens and to halt pandemics (5) . 75 Bacterial AB toxins are sophisticated nanomachines that rely on both specific measures against toxin-producing bacteria with broader applications in infectiology (2, 4) . 80 To enter the host cells, AB toxins exploit different endocytic pathways which converge 81 towards early endosomes from which they are dispatched to different vesicular pathways 82 (6) (7) (8) . AB toxins translocate their enzymatic part along the endolysosomal pathway or after 83 retrograde transport from the endoplasmic reticulum (ER), which represents another hot 84 spot of translocation (9, 10) . Early endosomes receive cargos, receptors and pathogenic 85 agents coming from the plasma membrane (11) . They serve as an essential sorting station 86 to re-route receptors and/or ligands to the cell surface through recycling endosomes, to the 87 trans-Golgi network and the ER through retrograde transport, or the lysosomes for 88 degradation. Each critical step along these vesicular pathways is specified by specialized 89 membrane-associated protein complexes (12) . Owing to their initial sorting functions, early 90 endosomes represent targets of interest to develop anti-infectives displaying a large 91 spectrum of action against toxin-producing bacteria and viruses. 92 The Cytotoxic Necrotizing Factor-1 (CNF1) toxin is produced by extraintestinal pathogenic 93 Escherichia coli responsible for urinary tract infections, neonatal meningitis and sepsis (13, 94 14) . The cnf1 gene also displays a prevalence estimated to 15% in E. coli sequence type (15) . CNF1 binds to Lu/BCAM and 67-kDa laminin receptor (67LR) to enter cells 98 and reaches acidic endosomes from which it translocates into the cytosol to deamidate 99 blocking protein synthesis. We also made use of Stx1 as it undergoes retrograde transport 154 from the early endosomes to the Golgi before reaching the ER where it exits into the 155 cytosol (10, 28) . The N-adenine glycohydrolase activity of Stx1 inhibits protein 156 biosynthesis. The cytotoxic effects induced by DT and Stx1 were quantified by a measure 157 of [ 14 C]-leucine incorporation into neosynthesized proteins. Among the 10 compounds 158 tested, three molecules turned to be active against DT and one of these was active 159 against Stx1 as well. Taken collectively, this screening strategy allowed us to isolate one Figure 1 ). We also evaluated the effective concentration of C910 169 against Exotoxin A (PE) from Pseudomonas aeruginosa, that shares with DT and STx the 170 capacity to inhibit protein biosynthesis. This toxin exploits intertwined endolysosomal and 171 retrograde pathways (29, 30) to reach the ER and get extruded into the cytosol (7, 31) . 172 Cells were intoxicated with increasing doses of PE in the presence of C910 or DMSO 173 vehicle establishing a value of EC50 of 12.6 μM ( Figure 1E and Sup. Figure 1A-D) . Finally, 174 we determined that C910 inhibited CNF1 (10 nM) with an IC50 = 11.3 μM ( Figure 1F ). We 175 showed that C910 exhibits no detectable toxicity on HUVECs and HeLa cells at 176 concentrations below 75 μM (Sup. Figure 1E ). Thus, we have identified a chemical entity 177 that decreases the susceptibility of host cells to five different bacterial toxins exploiting 178 defined intracellular trafficking pathways of intoxication. (Figure 2A and 2B). C910 had no impact on bacterial viability (data 190 not shown). We also verified in parallel that C910 abolished CNF1-mediated depletion of 191 Rac1 during cell infection ( Figure 2C ). In parallel, we found no protective effect of C910 on 192 the Cdc42/Rac1-dependent invasion of cells by Salmonella typhimurium (Figure 2D and E). 193 In contrast to CNF1 toxin-producing UPEC, cell-bound S. typhimurium directly injects 194 Cdc42/Rac1-activating effectors through the type-3 secretion system (T3SS)-1, thereby 195 bypassing endocytosis and intracellular trafficking steps required for AB toxins action (34). 196 The specificity of chemically-induced cellular protection against UPEC points toward an 197 action of C910 on the endocytic machinery that is exploited by CNF1, rather than an action 198 on Cdc42/Rac1-driven large-scale membrane deformations that are at play for cell 199 invasion by pathogenic bacteria. Extended spectrum of protection against bacterial AB-like toxins 202 We pursued the characterization of the antitoxin spectrum of C910 by studying a paradigm 203 of AB toxins that translocate their A-enzymatic components at acidic pH through a pore We went on to test the effect of C910 on large clostridial glucosylating toxins (LCGTs) 219 TcdA and TcdB from Clostridium difficile (40). These toxins hijack different host receptors 220 to enter into cells via endocytosis and translocate from acidified endosomes (41-43). The 221 internalization of LCGTs occurs via a dynamin-dependent process that largely involves 222 clathrin. LCGTs glucosylate a threonine residue in the effectors-binding loop of Rho 223 GTPases to short circuit the signaling cascades that control the actin cytoskeleton. 224 Consequently, this produces a rounding of cells. Highly sensitive Vero cells were 225 intoxicated with 8 cytotoxic units of TcdA or TcdB. These conditions were set to reach 226 100% of cell rounding at 8 h of intoxication. In these conditions, co-treatment of cells with 227 C910 at 5 μM markedly reduced the percentage of intoxicated cells ( Figure 3C ). The 228 extent of protection conferred by C910 on LCGTs cytotoxicity was quantified by anti-Rac1 229 immunoblotting ( Figure 3D ). This is based on the observation that glucosylation of the Altogether, our results show that C910 confers to host cell resistance against eight 236 bacterial AB toxins relevant to public health or produced by a pathogen of concern of 237 misuse.

238 239 C910 acts between CNF1 cell entry and catalytic steps 240 We showed that C910 protects cells against multiple AB toxins with distinctive catalytic 241 activities and host cell receptors, thereby pointing for a direct action on host cells.

Nevertheless, we verified the absence of an inhibitory effect of C910 on CNF1-mediated 243 deamidation of RhoA measured in vitro (Sup. Figure 2A) . We also verified that C910 did 244 not affect the association of CNF1 to cell surface-exposed receptors. For this, CNF1 was 245 chemically coupled to the Cy3 fluorophore (CNF1-Cy3) and incubated with cells at 4°C to 246 allow its binding to host cells. Fluorescence-activated cell sorting (FACS) analysis showed 247 that a concentration of C910 above its IC50 against CNF1, did not significantly alter the 248 mean fluorescence intensity (MFI) of CNF1-Cy3 bound to the cells ( Figure 4A ). We also 249 recorded an absence of effect of C910 on the cellular binding of the B-subunit of Shiga 250 toxin (STxB) (Sup. Figure 2B ). Furthermore, C910 had no detectable effect on the 251 internalization of CNF1-Cy3 and STxB ( Figure 4B ). Taken collectively, these data indicate 252 that C910 operates neither at initial steps of host cell receptor binding and endocytosis of 253 CNF1 and STxB nor at a later stage of CNF1 enzymatic activity.

These exploratory results prompted us to examine a broader impact of C910 on the 256 intracellular transport to lysosomes, by using a protease-dependent dequenching of self-257 quenched red fluorescent DQ TM Red BSA (DQ-BSA). At a late timing of the chase of 18 h, 258 we observed an accumulation of cleaved DQ-BSA with no detectable effect of C910 (data 259 not shown). When the chase was carried out during a shorter period of 4 h, we observed a 260 strong reduction of cleaved DQ-BSA in C910-treated cells, as compared to control 261 conditions ( Figure 4C ). In parallel, we recorded no significant effect of C910 on lysosomal 262 cathepsin B activity measured in vitro and in cells (Sup. Figure 3A and 3B). Together, 263 these data argue for an action of C910 on endolysosomal trafficking thereby preventing 264 toxin actions. particles that had an electron-lucent lumen and few internal vesicles (Sup. Figure 4C ). In 280 parallel, we recorded an increase in the size distribution of BSA-gold positive 281 compartments (Sup. Figure 4C ).

We went on to define how C910 treatment affects the trafficking of CNF1. After 90 min of 284 intoxication, CNF1-Cy3 accumulates in Rab7-positive late endosomes ( Figure 5C ). In 285 contrast, we observed that CNF1-Cy3 accumulates in the lumen of enlarged EEA1-286 positive endosomes in C910-treated HUVECs ( Figure 5C ). This was accompanied with a 287 significant decrease of co-localization between CNF1-Cy3 and Rab7 signals in C910-288 treated cells compared with control cells (Sup. Figure 5A ). In parallel, we found that C910 Figure 6A ) (53). This suggested a possible PIKfyve inhibition in C910 340 action. Nevertheless, we found that Apilimod had no protective effect on CNF1-mediated 341 degradation of Rac1 (Sup. Figure 6B ) and conversely C910 did not inhibit PIKfyve kinase 342 activity in vitro (Sup. Figure 6C ). In conclusion, C910 bears broad anti-infective properties 343 through a molecular mechanism different from that of Apilimod. Figure 7C and 7D).

When animals were challenged with a higher dose of virus in the same experimental 369 setting, we recorded that C910 treatment improved mice survival ( Figure 7B and 7C). attributed to the accumulation of C910 in lung tissues at an effective dose defined in vitro. 376 We conclude that C910 displays an extended protective spectrum against eight bacterial 377 AB toxins and two viruses via an original molecular mechanism of action on early 378 endosome sorting functions. Interestingly, we show that including orthogonal screens with DT and Stx1 is a stringent 397 procedure that nonetheless allows the identification of a compound targeting the two major 398 vesicular pathways hijacked by AB-like toxins, as compared to other anti-toxin chemicals 399 identified to date (Sup. Table 2 ). These compounds comprise EGA and ABMA that were 400 selected from HTS against the lethal toxin from Bacillus anthracis and the plant toxin ricin, 401 respectively (2, 4). Retro-2 was selected according to the same procedure than ABMA, 402 showing protection against ricin and Stx toxins (22). As summarized in the supplementary 403 Table 2 , these inhibitors display a specificity of action on a large panel of toxins trafficking 404 through one of the two major pathways, as opposed to the broader spectrum of action of 405 our newly discovered C910 compound. For example, C910 is able to inhibit Stx1/2, which 406 are excluded from the anti-toxin spectra of ABMA and EGA. Moreover, Retro-2 is devoid of 407 a protective effect against endolysosomal based-toxins, e.g. DT and CNF1 (unpublished 408 data). We have previously screened 1,120 off-patent drugs from the Prestwick Chemical Library 433 for their capacity to protect cells against CNF1-induced Rac1 depletion for drug 434 repurposing. Nevertheless, the identified compounds did not allow further development in 435 the clinic. Indeed, their antitoxin activities required concentrations higher than their safety 436 range, and in some instances, they had effects on multiple cellular organelles (58, 59).

The extended spectrum of protection conferred by C910 here points to its valuable anti-microbial resistance is a growing concern (5). Interestingly, we show that C910 446 displays a higher protection against Stx2 compared with Stx1. Each toxin hijack different 447 early endosome-Golgi transport pathways but Stx2 is responsible for triggering the 448 hemolytic and uremic syndrome as a consequence of STEC infection in humans (8) . 449 Owing to the synthesis of LCGTs, Clostridium difficile induces antibiotic and healthcare-450 associated diarrhea with roughly 10% mortality rate and a high recurrence rate of 451 approximately 20%. There is an urgent need in identifying novel treatments targeting 452 LCGTs pointing to the importance of further characterizing C910 mechanism of action (61).

The broad-spectrum of protection conferred by C910 also endows this molecule with 454 promise against toxins from Bacillus anthracis, a pathogen rarely responsible for human 455 infections and which is not the object of large vaccination campaigns but of concern of 456 misuse. Therefore, host-targeted therapy targeting host vesicular trafficking represents an 457 alternative strategy in the event of diversion of such a deadly pathogen. Samples were size-separated via SDS-PAGE, transferred to Immobilon-P PVDF 566 membranes (Millipore) and labelled by primary antibodies. Signals were revealed using 567 horseradish peroxidase-conjugated goat anti-mouse or swine anti-rabbit secondary 568 antibodies (DAKO) followed by chemiluminescence using Immobilon® Western (Millipore).

The chemiluminescent signals were recorded on a Syngene PXi imager (OZYME), and the 570 data were quantified using Fiji software (NIH).

Binding of CNF1 to cells analyzed by FACS All data are presented as mean ± s.d. or mean ± s.e.m., unless specified in the figure   662 legends. Student's t-tests were applied to determine the statistical significance between 663 two datasets and one-way ANOVA was used to perform analyses between more than two 664 datasets, unless specified in the figure legends. A value of p ≤ 0.05 was considered 665 significant (denoted * p ≤ 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). Graph Pad 666 Prism Software 8 was used to produce the graphs and to perform statistical analyses. Gupta, N, Noël, R, Goudet, A, Hinsinger, K, Michau, A, Pons, V, Abdelkafi, H Caprioli, A, Donelli, G, Falbo, V, Possenti, R, Roda, LG, Roscetti, G, Ruggeri, FM. Contamin, S, Galmiche, A, Doye, A, Flatau, G, Benmerah, A, Boquet, P. 2000.

The p21 Rho-activating toxin cytotoxic necrotizing factor 1 is endocytosed by a 

Retro-2 2-9 EGA 10 Sup. Figure S5 **** Sup. Figure S6 

A selective 1023

PIKfyve inhibitor blocks PtdIns(3,5)P(2) production and disrupts endomembrane 1024 transport and retroviral budding

The mammalian phosphatidylinositol 3-phosphate 5-1027 kinase (PIKfyve) regulates endosome-to-TGN retrograde transport

Characterization of 1031 spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with 1032 SARS-CoV

Screening of drug library identifies inhibitors of cell intoxication by 1035 CNF1

Revisiting 1037 old Ionophore Lasalocid as a novel inhibitor of multiple toxins

Antiviral Effects of ABMA against Herpes Simplex 1043 Virus Type 2 In Vitro and In Vivo

Retro-2 and its dihydroquinazolinone derivatives inhibit filovirus 1046 infection

The intersection of sex and gender in the treatment of 1048 influenza

Purification of 1052 two high molecular weight toxins of Clostridium difficile which are antigenically related

Transcriptome dysregulation by anthrax lethal 1056 toxin plays a key role in induction of human endothelial cell cytotoxicity

Early/recycling endosomes-to-TGN transport involves 1060 two SNARE complexes and a Rab6 isoform

Shiga toxin B-subunit as a tool to study retrograde 1062 transport

High-throughput screening 1065 identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS 1066 signaling

Escherichia coli alpha-Hemolysin Counteracts the Anti-Virulence Innate Immune 1071

Response Triggered by the Rho GTPase Activating Toxin CNF1 during Bacteremia

New low-viscosity 1074 overlay medium for viral plaque assays

CEA, INRAE, Département Médicaments et Technologies pour la Santé

Département Médicaments et Technologies pour la Santé, 1096 SCBM, 91191

Unité Génétique Moléculaire des Virus à ARN, UMR 3569 CNRS

Unité Technologie et service BioImagerie Ultrastructurale, Institut Pasteur, 28 rue du Dr Roux

Cellular and Chemical Biology unit, Endocytic Trafficking and 1118

1119 1120 # These authors contributed equally 1121 A: HUVECs were incubated with C910 or DMSO for the indicated periods of time, fixed, 1270 permeabilized and labeled for EEA1. Representative images are shown from two replicate 1271 experiments. Scale bar, 10 μm. B: HUVECs were incubated with different doses of C910 1272 or DMSO for 20 h and then processed as in (A). The size of EEA1-positive vesicles from at 1273 least 20 cells in each condition are quantified by

0001) with Dunnett's multiple comparison 1275 test to compare control and treated conditions, *** p < 0.001, ns: not significant. C: 1276 HUVECs were pre-treated with 20 µM C910 or DMSO

Representative electron micrographs are shown. White arrows 1279 indicate BSA-gold. Right, the size of BSA-gold positive compartments was quantified and 1280 data presented as mean ± s.e.m. for 87 (DMSO) and 77 (C910) compartments. Each point 1281 represents an individual compartment

Pearson's 1287 coefficient of two fluorescence (CNF1-Cy3 and Rab7) was analyzed with Fiji software and 1288 JACop plug-in. Data are presented as mean ± s.e.m. for 60 (DMSO) and 51 (C910) cells 1289 from three independent experiments. Each point represents an individual cell

Supplementary Figure S6. Distinctive mechanisms of action between Apilimod and 1293 C910

A: Representative images show EEA1 staining of HUVECs incubated with DMSO or 1295

Apilimod at the indicated concentration for 2 h. Scale bar, 10 μm

Apilimod has no significant protective effect at 1298 a broad range of concentrations. One representative experiment, n = 2. HUVECs were 1299 pre-incubated for 30 min with indicated concentrations of compounds prior to addition of 1300 CNF for 6 h. Anti-GAPDH was used as loading control. C: Representative images show 1301 radioactive labelled PI(3,5)P2 produced by recombinant PIKfyve in the presence of DMSO or 1302 compounds

Supplementary Figure S7. C910 PK, blood diagnostic and inhibition of IAV infection 1306 in vivo

A: PK parameters calculated for C910 following an intraperitoneal administration at 10

mg/kg in mice. Data are presented as mean ± s.e.m. of data from three experiments

Acute in vivo toxicology test was carried out on Balb/c mice. Five control animals received 1310 an i.p. injection of saline solution (0.9% NaCl) containing 5% DMSO and five animals 1311 received 20 mg/kg of C910 diluted in saline solution with 5% DMSO by the same route

Alanine aminotransferase 1314 (ALT), aspartate aminotransferase (AST), amylase (AMY), total bilirubin (TBIL), albumin 1315 (ALB), blood urea (BUN), creatinine (CRE), creatine kinase (CK). C-D: Survival (C) and 1316 weight (D) of mice following intranasal infection as in Figure 7A

Mantel-Cox test was performed to compare the survival curves 1319 between DMSO and C910 groups

A Novel Mass Assay to Quantify the Bioactive Lipid PtdIns3P in Various Biological Samples

Inhibition of Retrograde Transport Protects Mice from Lethal Ricin Challenge

Retrograde Trafficking Inhibitor of Shiga Toxins Reduces Morbidity and Mortality of Mice Infected with Enterohemorrhagic Escherichia Coli

Antiviral Effects of Retro-2cycl and Retro-2.1 against Enterovirus 71 in Vitro and in Vivo

Inhibitors of Retrograde Trafficking Active against Ricin and Shiga Toxins Also Protect Cells from Several Viruses, Leishmania and Chlamydiales

Retro-2 and Its Dihydroquinazolinone Derivatives Inhibit Filovirus Infection

Functional Dissection of the Retrograde Shiga Toxin Trafficking Inhibitor Retro-2

Targeting Host Syntaxin-5 Preferentially Blocks Leishmania Parasitophorous Vacuole Development in Infected Cells and Limits Experimental Leishmania Infections

Vaccinia Virus Uses Retromer-Independent Cellular Retrograde Transport Pathways To Facilitate the Wrapping of Intracellular Mature Virions during Virus Morphogenesis

Selective Inhibitor of Endosomal Trafficking Pathways Exploited by Multiple Toxins and Viruses

A Novel Inhibitor Prevents the Peripheral Neuroparalysis of Botulinum Neurotoxins

Semicarbazone EGA Inhibits Uptake of Diphtheria Toxin into Human Cells and Protects Cells from Intoxication

Identification of Agents Effective against Multiple Toxins and Viruses by Host-Oriented Cell Targeting

ABMA, a Small Molecule That Inhibits Intracellular Toxins and Pathogens by Interfering with Late Endosomal Compartments

DABMA: A Derivative of ABMA with Improved Broad-Spectrum Inhibitory Activity of Toxins and Viruses

Regulation of Endo-Lysosomal Pathway and Autophagic Flux by Broad-Spectrum Antipathogen Inhibitor ABMA

Antiviral Effects of ABMA against Herpes Simplex Virus Type 2 In Vitro and In Vivo